Uppsala 24thSeptember 2018
Nanexa strengthen the team with professor Axel Glasmacher as medical advisor
Nanexa has contracated Professor Axel Glasmacher as medical advisor to the drug product project within the cancer indications MDS (Severe myelodysplastic syndrome) and AML (Acute myeloid leukemia).
Professor Axel Glasmacher, MD, was until recently Senior Vice President and Head of the Global Clinical Research and Development Hematology Oncology at Celgene, where he has worked in various global roles for more than ten years. Prior to that, Professor Glasmacher worked within the fields of hematology-oncology at the University Hospital in Bonn.
Nanexas CEO David Westberg comments:
It is very important that we are able to work with persons with a world leading competence within the indication fields we focus on. For that reason, it is very gratifying that Professor Glasmacher, who has a long experience from pharmaceutical development within the MDS/AML indications, has accepted to support us in this development project. It will give us valuable input in the development work and will strengthen our commercial position going forward.
For further information:
Nanexa AB (publ)
David Westberg, VD
Phone: +46 709 42 83 03
E mail: firstname.lastname@example.org
About Nanexa AB (publ)
Nanexa AB is a nanotechnology drug delivery company focusing on the development of PharmaShell®, which is a new and groundbreaking drug delivery system that is expected to have great potential in a number of medical indications. Within the framework of PharmaShell®, Nanexa has partnership agreements with among others, AstraZeneca.